



Ministry of Food and Drug Safety

Osong Health Technology Administration Complex, 187, Osongsaengmyeong 2-ro,
Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, 28159, Republic of Korea,
Tel: +82-43-719-1010, Fax: +82-43-719-1000

Certificate of a Pharmaceutical Product

- No. of Certificate : 2020-A1-885
- Exporting (certifying) country : Republic of Korea
- Importing (requesting) country : Moldova, Republic of

1. Applicant (=Product-license holder)

(This certificate shall not be issued to others than the product-license holder)

- Name : Green Cross Corporation
- Address : 586, Gwahaksaneop 2-ro, Ochang-eup, Cheongwon-gu, Cheongju-si,
Chungcheongbuk-do, Republic of Korea

2. Name and dosage form of product

: Human Hepatitis B Immunoglobulin for Intravenous Administration

Product Name in Korean : 정주용 헤파빅주(정맥주사용 B형 간염 사람면역글로불린)

2.1. Number of product license and date of issue

: 495 / DEC. 28, 2006

2.2. Active ingredient(s) and amount(s) per unit dose

(For complete quantitative composition including excipients, see attached.)

: Each 1 ml contains

Human Hepatitis B Immunoglobulin----- 200 IU



2.3. Is this product licensed to be placed on the market for use in the exporting country ?

- └ Yes (○) ⇒ fill out section A, omit section B.
- └ No () ⇒ omit section A, fill out section B.

<p>A.1. Is this product actually on the market in the exporting country? Yes(○) / No() / Unknown()</p> <p>A.2. Is Summary Technical Basis of Approval appended? Yes() / No(○)</p> <p>A.3. Is the attached, officially approved product information complete and consonant with the license? Yes() / No() / Not provided(○)</p>
<p>B.1. Why is marketing authorization lacking?</p> <ul style="list-style-type: none"> └ not required (just Applicant's option, even possible) () └ not requested (not reviewed for marketing) () └ under consideration () └ refused () <p>B.2. Remarks (the reason not requesting registration) : Applying for tender</p>

2.4. Status of product-license holder

a (○) manufactures the dosage form

b () consigns wholly or partially the manufacturing process to other company :

- the manufacturer's
 - Name :
 - Address :
 - Consigned process :

c () is not involved in manufacturing process :

- the manufacturer's
 - Name :
 - Address :
 - Consigned process :



3. Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? YES

3.1. Periodicity of routine inspection(years) : 3 years

Inspection is determined by risk-based assessment under the provisions of the Pharmaceutical Affairs Act.

3.2. Has the manufacture of this type of dosage form been inspected? YES

3.3. Do the facilities and operations conform to the WHO-GMP?

Yes, it conforms to PIC/S and WHO GMP.

4. Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product? YES

※ Attached, if necessary : approved product information (X)

.....

Issued date : OCT. 06, 2020 (Certificate No.2020-A1-885)

Certified by Jeong hyun cheal

정 현 철

Director

Director for Novel Products Approval

Ministry of Food and Drug Safety

